ArticleBMJ case reports2015
Mucosal pigmentation of the hard palate in a patient taking imatinib.
Article in BMJ case reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.Clinical oral investigations · 2019Pooled it
- Pigmentary Changes Reported with Tyrosine Kinase Inhibitors: A Narrative Review of Mechanisms and Clinical Implications.Clinical drug investigation · 2026Review
- Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review.Healthcare (Basel, Switzerland) · 2024Review
- Oral Manifestations in Melanoma Patients Treated with Target or Immunomodulatory Therapies.Journal of clinical medicine · 2021Review
- Medication-Induced Oral Hyperpigmentation: A Systematic Review.Patient preference and adherence · 2020Review
- Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.Maxillofacial plastic and reconstructive surgery · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Imatinib mesylate is used in the treatment of chronic myeloid leukaemia, among other conditions. Oral mucosal pigmentation as a side effect is rare. We present a summary of the current literature and a case report of a 58-year-old Caucasian woman who presented with a diffuse blue-grey pigmentation of the palatal mucosa, thought to be related to long-term use of imatinib mesylate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.